Vivek Garipalli Increases CLOV Stake; Large Class B Convertible Holdings Disclosed
Rhea-AI Filing Summary
Vivek Garipalli, a director and 10% owner of Clover Health Investments (CLOV), reported purchases of Class A common stock on 08/07/2025 and 08/08/2025. He acquired 415,000 shares on 08/07/2025 at a weighted average price of $2.24 and 31,980 shares on 08/08/2025 at a weighted average price of $2.17, bringing his reported direct ownership to 1,856,247 Class A shares.
Table II discloses substantial Class B common stock that converts one-for-one into Class A: 6,904,343 Class A-equivalent shares held directly, plus 11,500,000 and 72,084,543 Class A-equivalent shares held indirectly by Caesar Clover, LLC and NJ Healthcare Investments, LLC, respectively. The filing states Garipalli serves as sole manager of those LLCs.
Positive
- Insider purchases reported: 415,000 shares at a weighted average of $2.24 and 31,980 shares at $2.17, increasing direct ownership.
- Direct ownership increased to 1,856,247 Class A shares following the transactions.
- Large convertible Class B holdings are disclosed that convert one-for-one into Class A, providing economic alignment between share classes.
- Reporting person is sole manager of Caesar Clover, LLC and NJ Healthcare Investments, LLC, clarifying the source of indirect holdings.
Negative
- High concentration of convertible holdings: Indirect holdings of 11,500,000 and 72,084,543 Class A-equivalents may concentrate voting/economic power.
- Incremental purchases are small relative to total convertible exposure, so the reported buys modestly change direct stake despite significant overall influence via Class B shares.
Insights
TL;DR: Material insider purchases alongside very large convertible Class B holdings, increasing direct stake modestly.
The Form 4 shows Garipalli purchased a total of 447,000 Class A shares across two days at weighted-average prices of $2.24 and $2.17, raising direct holdings to 1,856,247 shares. Equally important, Table II reports convertible Class B positions convertible one-for-one into Class A totaling tens of millions of shares (direct 6.9M; indirect 11.5M and 72.08M) held via two LLCs he manages. For investors, the filing confirms continued insider accumulation and concentrated voting/economic exposure via Class B instruments.
TL;DR: Insider buying is positive signal, but governance implications remain given concentrated Class B holdings held through managed LLCs.
The report documents incremental open-market purchases but also highlights that significant Class B convertible shares are held indirectly by Caesar Clover, LLC and NJ Healthcare Investments, LLC, entities for which Garipalli is sole manager. Those indirect holdings (11.5M and 72.08M Class A-equivalents) indicate concentrated control potential via convertible shares. The filing is informative about ownership structure but does not disclose any change in governance arrangements or conversion actions.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Class A Common Stock | 31,980 | $2.17 | $69K |
| Purchase | Class A Common Stock | 415,000 | $2.24 | $930K |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
| holding | Class B Common Stock | -- | -- | -- |
Footnotes (4)
- F1. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $2.16 to $2.32, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this Footnote 1 to this Form 4.
- F2. The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $2.15 to $2.21, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this Footnote 2 to this Form 4.
- F3. The Issuer's Class B Common Stock is convertible into shares of the Issuer's Class A Common Stock on a one-to-one basis at the option of the holders of the Issuer's Class B Common Stock at any time upon written notice to the Issuer, and automatically in the event of certain transfers, including, but not limited to, a transfer of shares to the Issuer.
- F4. The Reporting Person serves as the sole manager of each of NJ Healthcare Investments, LLC and Caesar Clover, LLC.
AI-generated analysis. How Rhea-AI works. Not financial advice.
